| Literature DB >> 35784571 |
Tian-Jiao Yuan1,2, Yu-Ying Yang1,2, Min-Ting Zhu1,2, Yang He1,2, Lin Zhao1,2, Wen-Zhong Zhou1,2, Ting-Wei Su1,2, Hong-Yan Zhao1,2, Li-Hao Sun1,2, Bei Tao1,2, Jian-Min Liu1,2.
Abstract
Background & Aims: Primary hyperparathyroidism(PHPT) has been evolving into a milder asymptomatic disease. No study has assessed the association between famine exposure and such a shift. We aim to explore the effects of China's Great Famine exposure on the changing pattern of PHPT phenotypes.Entities:
Keywords: adult exposure; clinical phenotype; early life exposure; famine; primary hyperparathyroidism
Mesh:
Substances:
Year: 2022 PMID: 35784571 PMCID: PMC9248378 DOI: 10.3389/fendo.2022.907019
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 6.055
Changes over time in demographic, clinical findings and famine exposure in patients with PHPT from 2000-2019.
| 2000-2009 (group A) | 2010-2019 (group B) | P-value | |
|---|---|---|---|
| Number of cases | 187 | 563 | |
| Sex (Female %) | 118 (63.4%) | 421 (74.8%) |
|
| Age (years) | 52.0 [42.0, 59.8] | 55.0 [46.0, 63.0] |
|
| Age at onset (years) | 50.6 [36.0, 58.3] | 51.9 [41.9, 60.0] | 0.127 |
| Disease duration (years) | 1.75 [0.23, 4.00] | 1.00 [0.25, 4.00] | 0.540 |
| BMI (kg/m2) | 21.9 [20.5, 24.4] | 22.9 [20.8, 25.3] | 0.090 |
| Serum PTH (pg/mL) | 423 [213, 1170] | 213 [138, 394] |
|
| Albumin-corrected serum calcium (mmol/L) | 2.95 [2.73, 3.30] | 2.73 [2.57, 2.92] |
|
| Serum phosphate (mmol/L) | 0.766 ± 0.192 | 0.883 ± 0.196 |
|
| Serum 25(OH)D (nmol/L) | 33.5 [23.3, 45.1] | 28.9 [20.7, 40.7] |
|
| Urinary calcium (mmol/24h) | 6.63 [5.02, 10.1] | 6.25 [4.42, 8.37] |
|
| Alkaline phosphatase (IU/L) | 123 [83.0, 229] | 92.0 [67.0, 129] |
|
| Tumor size (cm) | 2.50 [2.00, 3.20] | 1.70 [1.20, 2.45] |
|
| BMD (g/cm2) | |||
| L1-L4 | 0.911 ± 0.208 | 0.947 ± 0.196 | 0.129 |
| Femoral Neck | 0.725 ± 0.159 | 0.770 ± 0.150 |
|
| Total Hip | 0.757 ± 0.183 | 0.801 ± 0.155 |
|
| eGFR | 71.5 [48.5, 97.0] | 98.7 [81.9, 110] |
|
| Osteoporosis/Osteopenia | 95 (84.1%) | 281 (73.4%) |
|
| Fracture | 31 (17.3%) | 60 (10.7%) |
|
| Bone pain | 83 (46.4%) | 154 (27.4%) |
|
| Urolithiasis | 93 (52.0%) | 243 (43.2%) | 0.051 |
| Nausea and vomiting | 28 (15.6%) | 61 (10.8%) | 0.088 |
| Exposure | 135 (72.6%) | 329 (58.4%) |
|
| Fetal exposure | 13 (7.0%) | 64 (11.4%) | 0.096 |
| Childhood exposure | 63 (33.9%) | 176 (31.3%) | 0.526 |
| Adolescent exposure | 24 (12.9%) | 66 (11.7%) | 0.697 |
| Adult exposure | 35 (18.8%) | 23 (4.1%) |
|
| asymptomatic PHPT | 34 (18.3%) | 207 (36.8%) |
|
Data are expressed as the mean ± SD, median value [interquartile range] or as n (%), as appropriate. Significant associations are indicated in bold.
P < 0.05 was considered statistically significant.
PTH, parathyroid hormone; 25(OH)D, 25-hydroxyvitamin D; BMD, Bone mineral density; eGFR, estimated glomerular filtration rate.
The clinical data of primary hyperparathyroidism (PHPT) patients in famine exposure at different stages of life.
| Unexposed (Ref) | Fetal exposure | Childhood exposure | Adolescent exposure | Adult exposure | P-value | F vs Ref | C vs Ref | Ado vs Ref | Adu vs Ref | |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of cases | 285 | 78 | 239 | 90 | 58 | |||||
| Sex (Female %) | 188 (66.0%) | 61 (78.2%) | 183 (76.6%) | 72 (80.0%) | 36 (62.1%) |
| ||||
| Age (years) | 41.0 [33.0, 48.0] | 53.0 [49.0, 55.8] | 58.0 [55.0, 62.0] | 67.5 [64.0, 70.0] | 75.0 [71.0, 78.0] |
|
|
|
|
|
| Age at onset (years) | 38.0 [30.4, 45.9] | 51.0 [47.8, 54.2] | 56.0 [51.9, 60.0] | 64.7 [60.3, 68.0] | 72.5 [68.9, 77.0] |
| ||||
| Disease duration (years) | 1.00 [0.170, 4.00] | 1.00 [0.250, 4.08] | 1.00 [0.170, 4.00] | 1.75 [0.417, 5.00] | 1.00 [0.170, 3.25] | 0.294 | ||||
| BMI (kg/m2) | 23.57 ± 0.33 | 23.48 ± 0.41 | 22.81 ± 0.26 | 21.81 ± 0.49 | 21.18 ± 0.70 |
| 0.056 | |||
| Serum PTH (pg/mL) | 239.9 ± 51.4 | 482.2 ± 66.3 | 502.4 ± 40.5 | 703.9 ± 72.6 | 1112.9 ± 99.7 |
|
|
|
|
|
| Albumin-corrected serum calcium(mmol/L) | 2.72 ± 0.03 | 2.84 ± 0.04 | 2.86 ± 0.03 | 2.94 ± 0.05 | 3.20 ± 0.06 |
|
|
|
| |
| Serum phosphate (mmol/L) | 0.893 ± 0.018 | 0.840 ± 0.023 | 0.855 ± 0.014 | 0.806 ± 0.025 | 0.760 ± 0.034 |
|
| |||
| Serum 25(OH)D (nmol/L) | 35.41 ± 1.76 | 36.16 ± 2.25 | 32.80 ± 1.38 | 26.85 ± 2.69 | 31.66 ± 3.54 | 0.103 | ||||
| Urinary calcium (mmol/24h) | 6.87 ± 0.91 | 8.12 ± 1.21 | 8.34 ± 0.75 | 7.23 ± 1.36 | 9.11 ± 1.78 | 0.671 | ||||
| Alkaline phosphatase (IU/L) | 63.84 ± 27.23 | 173.53 ± 36.19 | 213.65 ± 21.78 | 332.01 ± 39.37 | 427.89 ± 55.03 |
|
|
|
| |
| Tumor size (cm) | 1.93 ± 0.10 | 2.24 ± 0.14 | 2.17 ± 0.09 | 2.24 ± 0.17 | 2.66 ± 0.23 | 0.134 | ||||
| BMD(g/cm2) | ||||||||||
| L1-L4 | 1.014 ± 0.020 | 0.949 ± 0.026 | 0.882 ± 0.018 | 0.868 ± 0.031 | 0.860 ± 0.044 |
|
|
|
| |
| Femoral Neck | 0.818 ± 0.016 | 0.780 ± 0.020 | 0.731 ± 0.014 | 0.671 ± 0.024 | 0.688 ± 0.033 |
|
|
|
| |
| Total Hip | 0.854 ± 0.017 | 0.801 ± 0.021 | 0.765 ± 0.015 | 0.702 ± 0.025 | 0.691 ± 0.035 |
|
|
|
| |
| eGFR | 98.36 ± 2.89 | 90.35 ± 3.88 | 90.25 ± 2.32 | 89.06 ± 4.18 | 76.54 ± 5.86 | 0.070 |
| |||
| Osteoporosis/Osteopenia | 121(61.1%) | 39(70.9%) | 122(85.9%) | 61(93.8%) | 34(91.9%) |
|
|
|
| |
| Fracture | 21 (7.5%) | 12 (15.4%) | 32 (13.6%) | 19 (21.6%) | 7 (12.1%) |
|
| |||
| Bone pain | 72 (25.6%) | 26 (33.3%) | 77 (32.5%) | 36 (40.9%) | 26 (44.8%) |
|
|
| ||
| Urolithiasis | 137 (48.1%) | 43 (55.1%) | 106 (44.4%) | 32 (35.6%) | 19 (32.8%) |
| ||||
| Nausea and vomiting | 23 (8.2%) | 8 (10.3%) | 36 (15.2%) | 10 (11.4%) | 13 (22.4%) |
|
| |||
| asymptomatic PHPT | 95 (33.3%) | 20 (25.6%) | 85 (35.6%) | 28 (31.1%) | 13 (22.4%) | 0.236 | ||||
P values is adjusted for age and sex. Data are expressed as the mean ± SEM, median value [interquartile range] or as n (%), as appropriate. Significant associations are indicated in bold. P < 0.05 was considered statistically significant.
PTH, parathyroid hormone; 25(OH)D, 25-hydroxyvitamin D; BMD, Bone mineral density; eGFR, estimated glomerular filtration rate
ORs (95%CIs) for related symptoms in PHPT patients with famine exposure at different stages of life.
| Model 1 OR(95%CI) | P value | Model 2 OR(95%CI) | P value | Model 3 OR(95%CI) | P value | |
|---|---|---|---|---|---|---|
|
| ||||||
| Unexposed | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) | |||
| Exposed |
|
|
|
|
|
|
| Fetal exposure | 1.55 (0.81,2.97) | 0.184 | 1.64 (0.79,3.40) | 0.183 | 1.54 (0.68,3.48) | 0.301 |
| Childhood exposure |
|
|
|
|
|
|
| Adolescent exposure |
|
|
|
|
|
|
| Adult exposure |
|
|
|
|
|
|
|
| ||||||
| Unexposed | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) | |||
| Exposed |
|
|
|
|
|
|
| Fetal exposure |
|
|
|
|
|
|
| Childhood exposure |
|
|
|
|
|
|
| Adolescent exposure |
|
|
|
|
|
|
| Adult exposure | 1.70 (0.69,4.21) | 0.252 | 4.36 (0.96,19.76) | 0.057 | 3.50 (0.47,25.96) | 0.220 |
|
| ||||||
| Unexposed | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) | |||
| Exposed |
|
|
|
| 1.20 (0.67,2.14) | 0.541 |
| Fetal exposure | 1.45 (0.84,2.49) | 0.178 |
|
| 1.31 (0.63,2.72) | 0.475 |
| Childhood exposure | 1.40 (0.95,2.05) | 0.086 |
|
| 1.52 (0.78,2.97) | 0.219 |
| Adolescent exposure |
|
|
|
| 2.56 (0.99,6.59) | 0.052 |
| Adult exposure |
|
|
|
|
|
|
|
| ||||||
| Unexposed | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) | |||
| Exposed | 0.81 (0.60,1.08) | 0.154 | 1.41 (0.89,2.24) | 0.143 |
|
|
| Fetal exposure | 1.29 (0.78,2.14) | 0.320 | 1.64 (0.93,2.89) | 0.090 | 2.04 (1.40,4.18) | 0.051 |
| Childhood exposure | 0.85 (0.60,1.20) | 0.360 | 1.14(0.68,1.91) | 0.628 | 1.53 (0.80,2.90) | 0.195 |
| Adolescent exposure |
|
| 0.91 (0.43,1.93) | 0.811 | 1.12 (0.43,2.89) | 0.819 |
| Adult exposure |
|
| 0.75(0.29,1.93) | 0.545 | 0.98 (0.28,3.38) | 0.973 |
|
| ||||||
| Unexposed | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) | |||
| Exposed |
|
| 1.69 (0.82,3.47) | 0.156 | 1.89 (0.81,4.45) | 0.143 |
| Fetal exposure | 1.29 (0.55,3.00) | 0.559 | 1.45 (0.56,3.75) | 0.439 | 1.51 (0.52,4.42) | 0.449 |
| Childhood exposure |
|
|
|
| 2.25 (0.85,5.94) | 0.103 |
| Adolescent exposure | 1.44 (0.66,3.16) | 0.359 | 1.92 (0.57,6.44) | 0.289 | 1.57 (0.38,6.39) | 0.531 |
| Adult exposure |
|
|
|
| 2.46 (0.44,13.86) | 0.307 |
Model 1: unadjusted.
Model 2: adjusted for age, gender.
Model 3: adjusted for age, gender, BMI, disease duration, eGFR.
Bold values represent results with statistical significance.
ORs (95%CIs) for upper 3rd serum PTH, albumin-corrected calcium levels and tumor size in PHPT patients with famine exposure at different stages of life.
| Model 1OR (95%CI) | P value | Model 2OR (95%CI) | P value | Model 3OR (95%CI) | P value | |
|---|---|---|---|---|---|---|
|
| ||||||
| Unexposed | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) | |||
| Exposed | 0.94 (0.68,1.29) | 0.693 |
|
|
|
|
| Fetal exposure | 1.22 (0.71,2.08) | 0.471 |
|
|
|
|
| Childhood exposure | 0.77 (0.52,1.12) | 0.175 |
|
|
|
|
| Adolescent exposure | 0.88 (0.52,1.47) | 0.617 |
|
|
|
|
| Adult exposure | 1.54 (0.86,2.77) | 0.145 |
|
|
|
|
|
| ||||||
| Unexposed | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) | |||
| Exposed | 1.08 (0.79,1.48) | 0.626 |
|
| 1.23 (0.68,2.23) | 0.486 |
| Fetal exposure | 1.06 (0.62,1.81) | 0.827 |
|
| 1.36 (0.65,2.86) | 0.420 |
| Childhood exposure | 0.90 (0.62,1.30) | 0.568 |
|
| 1.56 (0.79,3.08) | 0.198 |
| Adolescent exposure | 1.10 (0.66,1.82) | 0.719 |
|
| 1.86 (0.69,5.00) | 0.222 |
| Adult exposure |
|
|
|
|
|
|
|
| ||||||
| Unexposed | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) | |||
| Exposed | 0.84 (0.61,1.18) | 0.318 | 1.36 (0.83,2.24) | 0.222 | 1.38 (0.78,2.42) | 0.264 |
| Fetal exposure | 1.14 (0.64,2.03) | 0.655 | 1.76 (0.93,3.33) | 0.082 | 1.86 (0.90,3.83) | 0.094 |
| Childhood exposure | 0.79 (0.54,1.15) | 0.221 | 1.50 (0.86,2.61) | 0.153 | 1.38 (0.74,2.60) | 0.311 |
| Adolescent exposure |
|
| 1.45 (0.64,3.27) | 0.373 | 1.24 (0.49,3.18) | 0.649 |
| Adult exposure | 1.74 (0.79,3.82) | 0.170 |
|
|
|
|
Model 1: unadjusted.
Model 2: adjusted for age, gender.
Model 3: adjusted for age, gender, BMI, disease duration, eGFR.
Bold values represent results with statistical significance.